{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:34:53Z","timestamp":1789425293516,"version":"build-2803163510"},"reference-count":15,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:p>A dengue vaccine effective against all four serotypes is urgently needed. However, safety and immunogenicity could be affected by prior exposure to flaviviruses. This open, controlled, phase IIa study was conducted in 35 healthy adults who had received monovalent, live attenuated Vero cell-derived dengue vaccine against dengue virus 1 (VDV1) or 2 (VDV2) or yellow fever (YF) vaccine 1 year before or who were flavivirus-na\u00efve. All participants received one subcutaneous injection of tetravalent dengue vaccine (TDV) and were followed for 180 days. Previous vaccination did not increase reactogenicity, laboratory abnormalities, or incidence of vaccine viremia, but it did increase the neutralizing antibody response to dengue virus that persisted at day 180. There was no increase in YF antibodies in participants previously immunized with YF vaccine. Prior exposure to YF or monovalent dengue vaccines had no adverse effects on the safety or incidence of viremia associated with this TDV, but it increased immunogenicity.<\/jats:p>","DOI":"10.4269\/ajtmh.2011.10-0436","type":"journal-article","created":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T23:30:06Z","timestamp":1317857406000},"page":"724-731","source":"Crossref","is-referenced-by-count":57,"title":["Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans"],"prefix":"10.4269","volume":"85","author":[{"given":"Ming","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Forrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh","family":"Wartel-Tram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"R1","series-title":"Curr Opin Infect Dis","first-page":"429","article-title":"Immunopathological mechanisms in dengue and dengue hemorrhagic fever","volume":"19","author":"Green","year":"2006"},{"key":"R2","series-title":"Comp Immunol Microbiol Infect Dis","first-page":"329","article-title":"Dengue hemorrhagic fever with special emphasis on immunopathogenesis","volume":"30","author":"Kurane","year":"2007"},{"key":"R3","series-title":"J Virol","first-page":"5477","article-title":"Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates","volume":"74","author":"Guirakhoo","year":"2000"},{"key":"R4","series-title":"J Virol","first-page":"7290","article-title":"Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine","volume":"75","author":"Guirakhoo","year":"2001"},{"key":"R5","series-title":"Vaccine","first-page":"632","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010"},{"key":"R6","series-title":"J Infect Dis","first-page":"370","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all four serotypes in Flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010"},{"key":"R7","series-title":"Hum Vaccin","first-page":"60","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity. Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006"},{"key":"R8","series-title":"Vaccine","first-page":"1004","article-title":"Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections","volume":"20","author":"Monath","year":"2002"},{"key":"R9","series-title":"Vaccine","first-page":"5712","article-title":"Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects","volume":"26","author":"Guy","year":"2008"},{"key":"R10","series-title":"Vaccine","first-page":"4914","article-title":"Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)","volume":"24","author":"Sanchez","year":"2006"},{"key":"R11","series-title":"J Virol Methods","first-page":"40","article-title":"Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines","volume":"151","author":"Mantel","year":"2008"},{"key":"R12","series-title":"Trans R Soc Trop Med Hyg","first-page":"458","article-title":"A plaque technique for the titration of yellow fever virus and antisera","volume":"53","author":"Porterfield","year":"1959"},{"key":"R13","series-title":"Viral Immunol","first-page":"123","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses","volume":"21","author":"Roehrig","year":"2008"},{"key":"R14","series-title":"Am J Trop Med Hyg","first-page":"302","article-title":"Evaluation of interferences between dengue vaccine serotypes in a monkey model","volume":"80","author":"Guy","year":"2009"},{"key":"R15","series-title":"Pediatr Infect Dis J","first-page":"e9","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity","volume":"30","author":"Poo","year":"2011"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/85\/4\/article-p724.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/85\/4\/article-p724.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/85\/4\/article-p724.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:37:36Z","timestamp":1723059456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/85\/4\/article-p724.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":15,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.2011.10-0436","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,1]]}}}